These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 37623040)

  • 21. Durvalumab real-world treatment patterns and outcomes in patients with stage III non-small-cell lung cancer treated in a US community setting.
    Waterhouse D; Yong C; Frankart A; Brannman L; Mulrooney T; Robert N; Aguilar KM; Ndukum J; Cotarla I
    Future Oncol; 2023 Sep; 19(28):1905-1916. PubMed ID: 37497677
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of Immune-Related Adverse Events and Efficacy Outcomes With Consolidation Pembrolizumab After Chemoradiation in Patients With Inoperable Stage III Non-Small-Cell Lung Cancer.
    Shukla NA; Althouse S; Meyer Z; Hanna N; Durm G
    Clin Lung Cancer; 2021 Jul; 22(4):274-281. PubMed ID: 33610454
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC.
    Naidoo J; Antonia S; Wu YL; Cho BC; Thiyagarajah P; Mann H; Newton M; Faivre-Finn C
    J Thorac Oncol; 2023 May; 18(5):657-663. PubMed ID: 36841540
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non-Small-Cell Lung Cancer (PACIFIC).
    Socinski MA; Özgüroğlu M; Villegas A; Daniel D; Vicente D; Murakami S; Hui R; Gray JE; Park K; Vincent M; Mann H; Newton M; Dennis PA; Antonia SJ
    Clin Lung Cancer; 2021 Nov; 22(6):549-561. PubMed ID: 34294595
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients.
    Taugner J; Käsmann L; Eze C; Rühle A; Tufman A; Reinmuth N; Duell T; Belka C; Manapov F
    Invest New Drugs; 2021 Aug; 39(4):1189-1196. PubMed ID: 33704621
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Durvalumab after chemoradiotherapy for locally advanced non-small cell lung cancer prolonged distant metastasis-free survival, progression-free survival and overall survival in clinical practice.
    Yamamoto T; Tsukita Y; Katagiri Y; Matsushita H; Umezawa R; Ishikawa Y; Takahashi N; Suzuki Y; Takeda K; Miyauchi E; Saito R; Katsuta Y; Kadoya N; Jingu K
    BMC Cancer; 2022 Apr; 22(1):364. PubMed ID: 35379201
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical outcomes, local-regional control and the role for metastasis-directed therapies in stage III non-small cell lung cancers treated with chemoradiation and durvalumab.
    Offin M; Shaverdian N; Rimner A; Lobaugh S; Shepherd AF; Simone CB; Gelblum DY; Wu AJ; Lee N; Kris MG; Rudin CM; Zhang Z; Hellmann MD; Chaft JE; Gomez DR
    Radiother Oncol; 2020 Aug; 149():205-211. PubMed ID: 32361014
    [TBL] [Abstract][Full Text] [Related]  

  • 28. De-escalating adjuvant durvalumab treatment duration in stage III non-small cell lung cancer.
    Bryant AK; Sankar K; Zhao L; Strohbehn GW; Elliott D; Moghanaki D; Kelley MJ; Ramnath N; Green MD
    Eur J Cancer; 2022 Aug; 171():55-63. PubMed ID: 35704975
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment patterns and outcomes in early-stage ALK-rearranged non-small cell lung cancer.
    Schmid S; Garcia M; Cheng S; Zhan L; Chotai S; Balaratnam K; Khan K; Patel D; Catherine Brown M; Sachdeva R; Xu W; Shepherd FA; Sacher A; Leighl NB; Bradbury P; Moriarty P; Sara Kuruvilla M; Liu G
    Lung Cancer; 2022 Apr; 166():58-62. PubMed ID: 35183992
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Durvalumab-Associated Pneumonitis in Patients with Locally Advanced Non-Small Cell Lung Cancer: A Real-World Population Study.
    Lim CA; Ghosh S; Morrison H; Meyers D; Stukalin I; Kerba M; Hao D; Pabani A
    Curr Oncol; 2023 Dec; 30(12):10396-10407. PubMed ID: 38132391
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of interstitial lung abnormality on survival after adjuvant durvalumab with chemoradiotherapy for locally advanced non-small cell lung cancer.
    Kashihara T; Nakayama Y; Okuma K; Takahashi A; Kaneda T; Katagiri M; Nakayama H; Kubo Y; Ito K; Nakamura S; Takahashi K; Inaba K; Murakami N; Saito T; Okamoto H; Itami J; Kusumoto M; Ohe Y; Igaki H
    Radiother Oncol; 2023 Mar; 180():109454. PubMed ID: 36640944
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of the Efficacy and Toxicity of Concurrent Chemoradiotherapy and Durvalumab and Concurrent Chemoradiotherapy Alone for Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node Metastasis.
    Abe T; Iino M; Saito S; Aoshika T; Ryuno Y; Ohta T; Igari M; Hirai R; Kumazaki YU; Miura YU; Kaira K; Kagamu H; Noda SE; Kato S
    Anticancer Res; 2023 Feb; 43(2):675-682. PubMed ID: 36697072
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patients with unresectable stage III non-small cell lung cancer eligible to receive consolidation therapy with durvalumab in clinical practice based on PACIFIC study criteria.
    Sakaguchi T; Ito K; Furuhashi K; Nakamura Y; Suzuki Y; Nishii Y; Taguchi O; Hataji O
    Respir Investig; 2019 Sep; 57(5):466-471. PubMed ID: 31104989
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Timing of Adjuvant Durvalumab Initiation Is Not Associated With Outcomes in Stage III Non-small Cell Lung Cancer.
    Bryant AK; Sankar K; Strohbehn GW; Zhao L; Elliott D; Daniel V; Ramnath N; Green MD
    Int J Radiat Oncol Biol Phys; 2022 May; 113(1):60-65. PubMed ID: 35115216
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Prognostic Nutritional Index before durvalumab after chemoradiation predict the overall survival in patients with stage III non-small cell lung cancer.
    Matsuura S; Serizawa S; Yamashita R; Morikawa K; Ito Y; Hiramatsu T; Mochizuki E; Tanaka K; Akiyama N; Tsukui M; Koshimizu N; Kosugi T
    Ann Med; 2023 Dec; 55(1):2196089. PubMed ID: 37043179
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP).
    Faehling M; Schumann C; Christopoulos P; Hoffknecht P; Alt J; Horn M; Eisenmann S; Schlenska-Lange A; Schütt P; Steger F; Brückl WM; Christoph DC
    Lung Cancer; 2020 Dec; 150():114-122. PubMed ID: 33126091
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC).
    Faivre-Finn C; Spigel DR; Senan S; Langer C; Perez BA; Özgüroğlu M; Daniel D; Villegas A; Vicente D; Hui R; Murakami S; Paz-Ares L; Broadhurst H; Wadsworth C; Dennis PA; Antonia SJ
    Lung Cancer; 2021 Jan; 151():30-38. PubMed ID: 33285469
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Definitive Chemoradiation and Durvalumab Consolidation for Locally Advanced, Unresectable KRAS-mutated Non-Small Cell Lung Cancer.
    Guo MZ; Murray JC; Ghanem P; Voong KR; Hales RK; Ettinger D; Lam VK; Hann CL; Forde PM; Brahmer JR; Levy BP; Feliciano JL; Marrone KA
    Clin Lung Cancer; 2022 Nov; 23(7):620-629. PubMed ID: 36045016
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005/CRIMSON).
    Saito G; Oya Y; Taniguchi Y; Kawachi H; Daichi F; Matsumoto H; Iwasawa S; Suzuki H; Niitsu T; Miyauchi E; Yokoi T; Yokoyama T; Uenami T; Sakata Y; Arai D; Okada A; Nagata K; Teraoka S; Kokubo M
    Lung Cancer; 2021 Nov; 161():86-93. PubMed ID: 34543942
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of consolidation durvalumab after chemoradiation therapy for stage III non-small-cell lung cancer: a systematic review, meta-analysis, and meta-regression of real-world studies.
    Zhang Y; Tian Y; Zheng L; Sun X; Zhao Z; Zheng Y; Tian J
    Front Pharmacol; 2023; 14():1103927. PubMed ID: 37361225
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.